CDK5/p25 inhibitor (Pfizer)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameCDK5/p25 inhibitor (Pfizer)
Drug Alias Namecyclin dependent kinase 5/p25 inhibitors (Pfizer)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 5 activator 1 inhibitors
TargetsCyclin-dependent kinase 5 activator 1
Therapy Area/IndicationsNerve Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsNerve Degeneration

Other Information

ATC CodeN/A
Related LinksN/A